LEPTIN AND VISFATIN AS PREDICTORS OF GESTATIONAL HYPERTENSIVE COMPLICATIONS IN OVERWEIGHT WOMEN
DOI:
https://doi.org/10.21856/j-PEP.2024.2.01Keywords:
overweight, pregnancy, gestational hypertension, preeclampsia, leptin, visfatinAbstract
Background. Over the past decades, fatty tissue has ceased to be just an energy depot, but as a source of hormone-like peptides - adipokines, such as leptin and visfatin. There is a direct correlation between body weight and the risk of developing gestational complications. Aim of this study was to determine prognostic value of leptin and visfatin in predicting gestational hypertensive complications in overweight women.
Materials and methods. We examined 117 women divided into two groups: the main group included 68 overweight women, the control group included 49 women with normal body weight. Serum leptin and visfatin was established before pregnancy, in the first and third trimester.
Results. In overweight women, gestational hypertension was observed in 20 women (29.4%) and preeclampsia in 25 women (36.8%). The concentration of leptin in the third trimester during gestational hypertension increased by 21.9%, by 20.2% in preeclampsia compared before pregnancy (p<0.05) and exceeded the value in uncomplicated pregnancy by 1.3 times (p<0.05). In main group during third trimester in case of gestational hypertensive complications, the concentration of visfatin was higher than in women without complications (p<0.05). In the groups of women with hypertensive conditions, we observed significantly higher concentrations of visfatin compared with the woman without complications. In main group in case of gestational hypertensive complications, the concentration of visfatin was higher than in women without complications on the third trimester.
Conclusions. In overweight patients who developed hypertensive complications, leptin found to be 3.0 times higher before pregnancy and 2.0 times higher in the first trimester. Visfatin were found to be 1.2 times higher at both stages compared with control group. Leptin and visfatin may serve as qualitative predictors of hypertensive complications before pregnancy and during early gestation in overweight women.
References
Catalano PM, Shankar K. BMJ 2017;356: j1. http://doi.org/10.1136/bmj.j1.
Metwally M, Ong KJ, Ledger WL, Li TC. Fertil Steril 2008;90(3): 714-726 http://doi.org/10.1016/j.fertnstert.2007.07.1290.
O'Tierney-Ginn P, Presley L, Myers S, Catalano P. J Clin Endocrinol Metab 2015;100(1): 159-165. http://doi.org/10.1210/jc.2014-3281.
Dakroub A, Nasser S, Younis N, et al. Cells 2020;9(11): 2444. http://doi.org/10.3390/cells9112444.
Pestel J, Blangero F, Watson J, et al. Biochimie 2023;212: 48-59. http://doi.org/10.1016/j.biochi.2023.04.008
Vinood B. Patel. Molecular Nutrition: Carbohydrates. 2019: 53 p.
Obradovic M, Sudar-Milovanovic E, Soskic S, et al. Front Endocrinol (Lausanne). 2021;12: 585887. http://doi.org/10.3389/fendo.2021.585887.
Landecho MF, Tuero C, Valentí V, et al. Nutrients 2019;11(11): 2664. http://doi.org/10.3390/nu11112664.
Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Nutrients 2019;11(11): 2704. http://doi.org/10.3390/nu11112704.
Ostafiichuk SO, Henyk NI. Probl Endocrine Pathol 2019;69(3): 52-58. http://doi.org/10.21856/j-PEP.2019.3.07.
Pavlová T, Novák J, Bienertová-Vašků J. J Reprod Immunol 2015;112: 102-110. http://doi.org/10.1016/j.jri.2015.09.004.
Wnuk A, Stangret A, Wątroba M, et al. Obes Rev. 2020;21(7): e13022. http://doi.org/10.1111/obr.13022.
Shaheen A, Nazli R, Fatima S, et al. Pak J Med Sci 2016;32(6): 1419-1424. http://doi.org/10.12669/pjms.326.10917.
Amiri-Dashatan N, Koushki M, Hosseini H, et al. J Matern Fetal Neonatal Med 2022;35(13): 2606-2618. http://doi.org/10.1080/14767058.2020.1789581.
Radzicka-Mularczyk S, Zaborowski MP, Brązert J, Pietryga M. Minerva Endocrinol (Torino) 2021;46(4): 396-405. http://doi.org/10.23736/S2724-6507.20.03280-0.
Jahani F, Khazaei Z, Moodi M, et al. J Res Med Sci 2020;25: 80. http://doi.org/10.4103/jrms.JRMS_39_20.
Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi(vysokospetsializovanoi) medychnoi dopomohy: Hipertenzyvni rozlady pid chas vahitnosti, polohiv ta u pisliapolohovomu periodi: Nakaz № 151, 24 Jan. 2022, Ukraine, available at: https://www.dec.gov.ua/wp-content/uploads/2022/01/2022_151_ykpmd_giprozlvagitn.pdf
Mishra P, Pandey CM, Singh U, et al. Ann Card Anaesth 2019;22(3): 297-301. http://doi.org/10.4103/aca.ACA_248_18.
Peltokorpi A, Irina L, Liisa V, Risto K. Hypertens Pregnancy 2022;41(1): 70-77. http://doi.org/10.1080/10641955.2022.2033763.
Kobrynska, O, Didushko O. Probl Endocrine Pathol 2022;79(1): 36-42. http://doi.org/10.21856/j-PEP.2022.1.05.
Veiga ECA, Korkes HA, Salomão KB, Cavalli RC. Front Pharmacol 2022;13: 966400. http://doi.org/10.3389/fphar.2022.966400.
Beneventi F, Locatelli E, De Amici M, et al. J Matern Fetal Neonatal Med 2020;33(23): 3942-3948. http://doi.org/10.1080/14767058.2019.1593359.
Chandrasekaran S, Hunt H, Melhorn S, et al. J Matern Fetal Neonatal Med 2020;33(16): 2812-2817. http://doi.org/10.1080/14767058.2018.1562542.
Mlyczyńska E, Zaobidna E, Rytelewska E, et al. Anim Reprod Sc. 2023;250: 107212. http://doi.org/10.1016/j.anireprosci.2023.107212.
Nunes PR, Cavalli RC, Belo VA, et al. Reprod Sci 2023;30(10): 2893-2895. http://doi.org/10.1007/s43032-023-01246-4.
ISSN 
ISSN 
